Thomas Keane to Kallikreins
This is a "connection" page, showing publications Thomas Keane has written about Kallikreins.
Connection Strength
0.074
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
Score: 0.038
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
Score: 0.036